Biotechnology company Baebies has secured de novo clearance from the US Food and Drug Administration (FDA) for the use of its newborn screening platform SEEKER in diagnosis of lysosomal storage diseases (LSDs).

The new device is designed to quantitatively measure the activity of lysosomal enzymes α-L-iduronidase (IDUA), α-D-glucosidase (GAA), β-glucocerebrosidase (GBA) and α-D-galactosidase A (GLA) in dried blood spot samples of newborns.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The detection of a decrease in the activity of these lysosomal enzymes indicates the presence of LSDs such as Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher or Fabry.

Baebies president and co-founder Vamsee Pamula said: "Although these LSDs have FDA approved therapies, this is a significant milestone for the LSD community, as SEEKER is the first FDA cleared product for LSD testing.

"FDA's clearance of SEEKER resulted from a thorough and rigorous review.

"We look forward to providing SEEKER kits to implement safe, effective, easy and reliable screening for LSDs. SEEKER is the only FDA authorised test on the market."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initiated to ensure the screening of all babies for certain serious conditions at birth, the Newborn screening health programme currently includes more than 30 metabolic and genetic diseases.

"This is a significant milestone for the LSD community, as SEEKER is the first FDA cleared product for LSD testing."

The Pompe disease and MPS I were recently included in the Recommended Uniform Screening Panel (RUSP), enabling early detection of LSDs via newborn screening.

It is expected that the FDA clearance will allow to reduce the validation effort with the implementation of the cost effective screening.

Baebies develops new technologies and tests for advance newborn screening and pediatric testing.

Image: SEEKER Instrument. Photo: courtesy of Baebies.